

United Ventures leads InSilicoTrials' €3 Million Series A Financing Round to Democratize Simulations in Healthcare and Life Sciences

The investment round, led by United Ventures with participation from venture fund Pi Campus, will help pharmaceutical and medical device companies to make modeling & simulation technology accessible and develop innovations much faster and at lower cost

Milan, 27 July 2020 - [United Ventures](#), independent Italian venture capital fund specializing in investments in digital technologies, is the lead investor in the **€3 million Series A** funding of [InSilicoTrials](#), the company that enables pharmaceutical and medical device companies to accelerate research and development activities through a collaborative platform of simulation models. [Pi Campus](#), a venture fund that invests in artificial intelligence and Italian excellence, also participated in the round.

InSilicoTrials operates in the field of **in silico technology**, a term used to refer to clinical trials through computer simulations. Through the development of artificial models, researchers are able to assess the safety, efficacy, and risks of biomedical devices and pharmacological treatments with a view to their commercialization.

The platform developed by InSilicoTrials **reduces product development time and costs from 40% to 60%**, including those required to **obtain regulatory approvals**. Thanks to its pay-per-use model, it makes the simulation world available not only to a few market leaders but to all the more than 52,000 medical companies and 3,200 pharmaceutical companies operating in the market. Interest in *in silico* technology is growing: the [global biosimulation market](#) has been estimated at about \$1.65 billion in 2018 and is expected to generate about \$4.58 billion by 2025, with a CAGR of about 15.7% between 2019 and 2025.

Costs and times of clinical trials have always been a sore point for companies in the pharmaceutical and biomedical sector - and the health emergency of recent months has made this even more evident. Today, an average of **2.6 billion dollars and up to 12 years** of experimentation and dialogue with regulatory bodies are needed to bring a new drug to market. **95%** of potential drugs, as a result of laboratory testing and clinical trials, do not reach it at all.

Among the major competitive advantages of InSilicoTrials are the **strong reputation** in the scientific community and the relationship developed over the years with **healthcare regulators**, who strongly support the implementation and use of modeling and simulation (M&S) practices for preclinical studies and clinical trials.

The founder and CEO of InSilicoTrials, **Luca Emili**, is a member of the Cloud Security Consultative Group of **EMA (European Medicines Agency)** and a leader in the Avicenna Alliance - an association for predictive medicine that brings together research organizations and industry leaders such as Medtronic, Johnson & Johnson, Cipla, Servier and Boston Scientific - of the task force working with the **FDA (Food and Drug Administration)** on Good Simulation Practices for Health Technologies. The initiative is also supported by the European Economic and Social Affairs Committee (EESC) of the European Commission, as part of the proposals to combat Covid-19. Before InSilicoTrials, Luca Emili was the founder of Promeditec, a company operating in the field of automation for clinical trials, and before that, he was CEO of Emaze and professor at the MIB School of Management in Trieste.

At the head of the research and development department, there is the co-founder **Roberta Bursi**, Ph.D. in computational chemistry and over 25 years of experience in the drug&med tech sector (Organon, Schering-Plough, Merck, Grunenthal) who in the pharmaceutical sector has carried out significant innovations using models also in the development and approval of drugs for the pediatric sector.

*"The company's goals are very ambitious: to become the benchmark for healthcare modeling and simulation (M&S) and revolutionize it to improve the quality of life and care of patients around the world," says **Luca Emili**, founder and CEO of InSilicoTrials. "If we want to make medical care really affordable for everyone, if we want to realize the dream of personalized medicine where the doctor, in the hospital, is able to prepare complex surgical operations or print in 3D prostheses that must work perfectly, then it is necessary to look at technologies such as numerical simulation integrated into clinical trials. And it is necessary to evolve the research model that today is proving to be increasingly slow and inefficient, expensive and unsuitable to respond to needs such as those of personalized medicine".*

According to **Massimiliano Magrini**, managing partner of United Ventures, *"Unlike the aerospace or automotive sector, Healthcare & Life Sciences have yet to be disrupted by the revolutionary scope of simulation software. InSilicoTrials aims to bring the logic of digitization through the development of an accessible and interoperable platform to a sector as critical for the collective well-being as the development of drugs and medical devices, enhancing the models produced by scientific research. A project in which we found those characteristics - technology, vision, entrepreneurial spirit - that guide our investment thesis".*

**Press Office United Ventures
iCorporate**
Arturo Salerni
+39 338 5220260
arturo.salerni@icorporate.it

Press Office Pi Campus
Silvio Gulizia
silvio@picampus.it

[United Ventures SGR SpA](#) is an independent Italian venture capital firm specialized in investments in innovative companies in digital technologies. Founded in 2013 by Massimiliano Magrini and Paolo Gesess, United Ventures manages over 190 million euros raised by Italian and international institutional investors and has invested to date in over 20 early-stage technology companies. The current portfolio includes, among others: Fiscozen, xFarm, MishiPay, Equalum, Exein, Credimi, brumbrum, Moneyfarm, Cloud4Wi, MusiXmatch, MainStreaming, and FACEIT.

[InSilicoTrials](#) is a company founded in 2017 in Trieste by Luca Emili and Roberta Bursi. InSilicoTrials aims to revolutionize the pharmaceutical and biomedical sector, offering the first web platform in the world that democratizes access to tested and validated simulation models for the clinical trial of drugs and medical devices.

It is based on two key elements: on the one hand, the company works with researchers, regulatory agencies, and universities around the world to identify the best mathematical models available for the medical sector. These models are then integrated into the web platform, which becomes a constantly growing catalog. The second part consists precisely in making the models usable in a simple way, within a secure IT infrastructure and by personnel who, while having a high level of scientific preparation, are not necessarily experts in modeling & simulation.

The InSilicoTrials team is composed of engineers and computer scientists with extensive experience and know-how in the research and development processes of medical devices and pharmaceuticals, modeling, numerical simulation in biomedical and biomechanical, health regulations and regulations, and IT development.